Rotator cuff tears rank among the most common and most expensive shoulder injuries workers’ compensation claims professionals see, and the surgery used to fix them fails at a surprisingly high rate — published estimates range from roughly 11 percent to as high as 94 percent depending on tear size, tissue quality, and patient age. On August 31, 2026, medical device giant Stryker announced a definitive agreement to acquire ZuriMED, a Zurich-based company whose FiberLocker System is designed to directly address one of the most common reasons those repairs fail.
A rotator cuff tear occurs when one or more of the tendons connecting the shoulder muscles to the upper arm bone tears away from its attachment point, often from a fall, a sudden overhead strain, or cumulative wear from repetitive overhead work — all common workers’ compensation injury mechanisms. Surgical repair typically involves reattaching the torn tendon to bone using suture anchors, small devices implanted in the bone that hold stitches passed through the tendon.
The problem is that the tendon tissue itself is often the weak link. In many patients, particularly those with larger or more chronic tears, degenerated or poor-quality tendon tissue cannot hold sutures securely, and the repair can pull through or re-tear before the tendon has had time to biologically heal back to bone. This failure mode — suture pull-through in weakened tissue — is distinct from anchor failure or surgical technique error, and it has proven difficult to solve through suture or anchor design alone.
ZuriMED’s FiberLocker System, which received FDA 510(k) clearance in late 2024, is a soft-tissue augmentation technology in which a polyester patch is applied over the repaired tendon during or after surgery and secured to the surrounding tissue. The device is designed to reinforce the connection between the sutures and the tendon, distributing mechanical load across a broader area of tissue rather than concentrating stress at the suture points, with the goal of reducing the specific failure mode of sutures cutting through weakened tendon.
According to Stryker’s announcement, the company will add the commercialized FiberLocker System to its existing shoulder portfolio, supporting both sports medicine and arthroplasty applications. Financial terms were not disclosed, and the deal remains subject to customary closing conditions, with ZuriMED continuing to operate as a separate entity until closing. Andy Pierce, Stryker’s Group President of MedSurg and Neurotechnology, said the technology “addresses an important clinical need within shoulder care,” and the company has characterized rotator cuff augmentation as one of the fastest-growing segments within sports medicine.
Rotator cuff injuries will remain a persistent and costly category of workers’ compensation claims regardless of how this particular acquisition plays out, but the broader trend it reflects — device manufacturers investing specifically in technologies aimed at reducing surgical failure rates rather than only expanding surgical volume — is one claims professionals should continue to track.
As FiberLocker and similar augmentation technologies see wider adoption following Stryker’s acquisition, expect more surgeons to raise augmentation as a treatment option, and expect the evidentiary record on its real-world effectiveness to grow correspondingly. Claims professionals reviewing shoulder treatment requests should ask what tear characteristics are driving a given surgical recommendation and whether augmentation, if proposed, is supported by the claimant’s specific clinical picture rather than applied as a routine add-on.